로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > BTLA

BTLA

Brief Information

Name:B- and T-lymphocyte attenuator
Target Synonym:BTLA,B- and T-lymphocyte attenuator,B- and T-lymphocyte-associated protein,B And T Lymphocyte Associated,CD272 Antigen,BTLA1,CD272
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

SCJUR-STF106-Cell-based assay
 BTLA FACS

Expression analysis of human BTLA on Human BTLA (Luc) Jurkat Reporter Cell by FACS.
Human BTLA (Luc) Jurkat Reporter Cell or negative control cell were stained with PE-labeled anti-human BTLA antibody.

SCCHO-ATP110-Cell-based assay
 BTLA FACS

Expression analysis of human BTLA on CHO/Human BTLA Stable Cell Line by FACS.
Cell surface staining was performed on CHO/Human BTLA Stable Cell Line or negative control cell using PE-labeled anti human BTLA antibody.

BTA-H52H3-BLI
 BTLA BLI

Loaded Human BTLA (31-150), His Tag (Cat. No. BTA-H52H3) on NTA Biosensor, can Human HVEM, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. HVM-H5255) with an affinity constant of 20.8 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

BTA-H82E4-ELISA
 BTLA ELISA

Immobilized Biotinylated Human BTLA (31-150), His,Avitag (Cat. No. BTA-H82E4) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human HVEM, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. HVM-H5255) with a linear range of 2-78 ng/mL (QC tested).

Synonym Name

BTLA,CD272

Background

B- and T-lymphocyte attenuator (BTLA) is also known as B- and T-lymphocyte-associated protein, CD antigen CD272. BTLA contains one Ig-like V-type (immunoglobulin-like) domain. As a lymphocyte inhibitory receptor, BTLA / CD272 inhibits lymphocytes during immune response. BTLA / CD272 can interact with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2, and interact with TNFRSF14/HVEM.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ANB-032 ANB-032 Phase 1 Clinical Anaptysbio Inc Inflammation Details
LY-3361237 LY-3361237 Phase 2 Clinical Eli Lilly And Company, Sanford-Burnham Medical Research Institute Lupus Erythematosus, Systemic; Psoriasis Details
Tifcemalimab TAB-004; JS-004 Phase 2 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Nasopharyngeal Carcinoma; Lung Neoplasms; Lymphoma; Neoplasm Metastasis; Melanoma Details

This web search service is supported by Google Inc.

totop